Holen Sie sich die Stockscreener-App
85.46
0.64%
0.54
Handel nachbörslich:
85.95
0.49
+0.57%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte to Present at Upcoming Investor Conferences - MarketScreener
Will Incyte Corporation Reverse From Oversold ConditionsJuly 2025 Intraday Action & Daily Risk Controlled Trade Plans - metrotimes.co.kr
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers - Yahoo Finance
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte Corp (INCY) Set to Outperform Market: Strong Financial Growth and Competitive Advantage - AInvest
Cancer Stock Soars While This China Tech Stock Heads To New Highs - Investor's Business Daily
Incyte CFO Christiana Stamoulis to Step Down in September - MSN
Stock Analysis | Incyte OutlookMixed Signals Amid Rising Price and Strong Fundamentals - AInvest
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Incyte's 5.2% Surge on $270M Volume Ranks 430th Amid FDA Approval and Strategic Shifts - AInvest
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - Yahoo Finance
Incyte stock hits 52-week high at 83.95 USD - Investing.com
The Top 5 Analyst Questions From Incyte’s Q2 Earnings Call - Yahoo Finance
Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight - Insider Monkey
Trapped Investors in Incyte Corporation Await Breakout SignalPortfolio Diversification Stock Ideas From Experts - beatles.ru
Incyte EVP Denton sells $45k in shares after option exercise - Investing.com Australia
Semerjian to lead Geron - BioCentury
Incyte EVP Denton sells $45k in shares after option exercise By Investing.com - Investing.com South Africa
Incyte (INCY) Analyst Rating: Wells Fargo Upgrades to Overweight - GuruFocus
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - The Manila Times
Mallinckrodt appoints Incyte’s Christiana Stamoulis as new CFO - Investing.com
Wells Fargo Upgrades Incyte to Overweight From Equalweight, Adjusts Price Target to $89 From $67 - MarketScreener
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis - BioSpace
Incyte CFO Christiana Stamoulis to step down in September - Investing.com
Incyte CFO Christiana Stamoulis to step down in September By Investing.com - Investing.com UK
Argus Research Adjusts Incyte Price Target to $90 From $75 - MarketScreener
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Mizuho Securities Adjusts Incyte Price Target to $74 From $70 - MarketScreener
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - MSN
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Nigeria
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte: Q2 Earnings Snapshot - Huron Daily Tribune
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
0.22%
3.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):